Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Other material
confidence 72%
filed 2026-08-10
Embraer revised its 2026 guidance, materially increasing Adjusted EBIT Margin (from 8.7%-9.3% to 10.0%-10.6%) and Free Cash Flow (from $200M+ to $400M+) while maintaining revenue and delivery guidance. This is a forward-looking guidance update that would affect investor assessment, but it does not fit neatly into the discrete event taxonomy—it is neither a results announcement (earnings_release), a financial obligation (debt_issuance), nor an operational restructuring. The disclosure is labeled "MATERIAL FACT" under Brazilian CVM rules and represents management's revised view of 2026 performance.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-10
This is Embraer's 2nd Quarter 2026 earnings results disclosure, presented as a comprehensive earnings release with detailed financial statements, operational metrics, and forward guidance. The document explicitly states "2nd QUARTER 2026 EARNINGS RESULTS" and includes consolidated revenue of US$2,235 million (+23% yoy), Adjusted EBIT of US$296.9 million with 13.3% margin, and updated 2026 guidance raising Adjusted EBIT margin guidance from 8.7%-9.3% to 10.0%-10.6%. This is a material event affecting investor assessment of the registrant's financial performance and outlook.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-10
This 6-K furnishes Embraer's Q2 2026 financial results as a press release. The document discloses "Best Q2 revenue in the company's history (US$2.2 bn)," detailed segment revenues and EBIT margins, updated 2026 guidance (revenue US$8.2–8.5B, EBIT margin 10.0–10.6%, FCF >US$400M), and key operational metrics (65 aircraft deliveries, US$34.5B backlog). These are material quarterly earnings that would affect a reasonable investor's assessment of the registrant's financial performance and outlook.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-08-10
The filing discloses that CSN has received binding proposals from potential purchasers in a competitive process for the "potential full divestment of its subsidiary CSN Cimentos S.A." This constitutes material M&A activity — specifically a disposition or sale of a subsidiary. The company explicitly references a prior Material Fact disclosure from January 15, 2026, and states it is "currently evaluating the binding proposals," indicating an active transaction process that would materially affect the registrant's asset base and financial position.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-10
This is a formal earnings release for the second quarter of 2026 (6M26) filed by EDENOR, Argentina's largest electricity distributor. The document presents comprehensive financial results including revenues (ARS 918.5 billion in 2Q26, +10% vs 2Q25), EBITDA (ARS 313.7 billion for 6M26), net profit (ARS 31.3 billion in 2Q26), operating expenses, capital expenditures, and detailed operating indicators. The company explicitly announces results and schedules a webcast for August 11, 2026, with CFO German Ranftl to discuss the 2Q26 results, which is typical of a formal earnings announcement.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-08-10
EDENOR announced on August 10, 2026, that it has accepted an offer to acquire 70% of YPF's shareholding in MetroGAS S.A. and 5% of YPF's shareholding in MetroENERGÍA S.A. for US$780 million. This is a material acquisition transaction disclosed as a "Material Fact" to Argentine securities regulators, representing a significant expansion of EDENOR's energy distribution portfolio and a substantial capital commitment.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Brookdale Senior Living announced second quarter 2026 financial results, reporting consolidated net income of $23 million (versus a $43 million loss in Q2 2025), Adjusted EBITDA of $122 million (4.3% growth), RevPAR growth of 8.2% year-over-year, and occupancy improvements of 230 basis points, along with full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-08-10
Item 1.01
The Company entered into the Sixth Amendment to its credit facility, extending the maturity date to January 12, 2028, reducing revolving commitments from $100M to $54M, removing the Incremental Delayed Draw Term Loan facility, and adjusting leverage covenants to provide financial flexibility.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
The Company issued a press release announcing consolidated operating results for Q2 and H1 2026, reporting net revenues of $424.0 million, net income from continuing operations of $81.9 million, and Adjusted EBITDA of $91.5 million, along with 2026 guidance of $320–$365 million in Subsidiary Adjusted EBITDA.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
Palisade Bio issued a press release on August 10, 2026 announcing financial results for the three and six months ended June 30, 2026, including condensed consolidated balance sheets, statements of operations, and cash flow statements. The disclosure includes key financial metrics (net loss of $10.6 million for Q2 2026 vs. $2.8 million for Q2 2025, cash position of $125.2 million) and material operational updates on PALI-2108 Phase 2 development progress. This is a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-10
Item 5.07
NVE Corp held its 2026 Annual Meeting on August 6, 2026, with shareholders voting on three proposals: election of seven directors, advisory approval of named executive officer compensation, and ratification of independent auditor Boulay PLLP. All three proposals passed with overwhelming majorities.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-10
Item 5.02
Peter G. Eames was appointed as president and chief executive officer and elected to the Board of Directors, succeeding Daniel A. Baker who retired from the CEO role. Carolyn W. Valentine was also elected to the Board.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
Green Dot Corporation issued a press release on August 10, 2026 announcing its financial results for the quarter ended June 30, 2026, including consolidated revenue of $595.9 million, net loss of $2.1 million, and adjusted EBITDA of $40.2 million. The disclosure is furnished as Exhibit 99.01 and constitutes a standard quarterly earnings release under Item 2.02, with detailed segment results and key business metrics.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-10
Item 8.01
Aquestive disclosed positive topline results from human factors validation and pharmacokinetic studies for its investigational drug Anaphylm, directly addressing FDA concerns from a Complete Response Letter and supporting a planned NDA resubmission to the FDA in Q3 2026. These study results represent a material clinical and regulatory milestone for the company's lead product candidate and are critical to its path toward regulatory approval.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a clear earnings release disclosing Bionano's Q2 2026 financial results for the period ended June 30, 2026. The press release reports total revenue of $8.2 million (21% YoY increase), consumables revenue of $4.3 million (31% increase), gross margin of 53%, and provides forward guidance for Q3 and full-year 2026. The filing is properly classified under Item 2.02 (Results of Operations and Financial Condition) with the full press release attached as Exhibit 99.1, which is the standard format for earnings disclosures.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-10
Item 7.01
The Board declared a cash dividend of $0.15 per share payable on September 30, 2026, to stockholders of record as of September 15, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The disclosure includes total revenues of $29.0 million (up 13% YoY), licensing revenues of $18.2 million (up 21%, highest in three years), royalty revenues of $10.8 million, GAAP net loss of $2.9 million, and non-GAAP net income of $2.3 million. The earnings release is attached as Exhibit 99.1 and includes full financial statements and management commentary on business performance and market highlights.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-10
Item 2.01
Byrna Technologies Inc. completed the acquisition of substantially all assets of Hero Defense Systems, LLC on August 6, 2026, for aggregate consideration of $625,000 cash, 104,000 restricted shares, assumption of liabilities, and a 3.5% royalty stream. The acquisition expands Byrna's product portfolio into Hero's less-lethal defense products business.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-10
Item 8.01
Clene disclosed new biomarker analyses from Phase 2 ALS trials showing CNM-Au8 efficacy in NfL-responsive patients, with findings to be included in a planned NDA submission for accelerated FDA approval. This represents a material clinical and regulatory milestone for the company's lead therapeutic candidate, directly addressing FDA feedback from a prior Type C meeting.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-10
Item 7.01
Trump Media is disclosing a strategic shift in its business operations: the termination of two Crypto.com deals (the CRO Strategy venture and prediction-market integration) and a pivot toward simpler monetization of its Truth Social platform through data licensing and API services. While the Item 7.01 disclosure itself is a Regulation FD furnishing of a press article, the underlying event—a material change in business strategy and termination of previously announced ventures—is an operational matter that would affect investor assessment of the company's direction and capital allocation, particularly given the pending TAE merger. This does not fit the specific operational categories (workforce reduction, material contract) but represents a significant strategic repositioning.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-10
Item 7.01
Art's-Way announced that its Modular Buildings segment was awarded major projects, increasing backlog from $1.3 million to over $19.0 million—a material increase in production commitments and future revenue visibility. This is a significant operational/business development event, but does not fit the specific categories of M&A activity, debt issuance, or other named types. The disclosure is material to investors as it substantially strengthens the company's forward-looking production activity and revenue pipeline.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Mesa Laboratories issued a press release on August 10, 2026 disclosing quarterly financial results for the three months ended June 30, 2026 (1Q27). The filing includes detailed revenue, operating income, net income, and divisional performance metrics, along with non-GAAP reconciliations and management commentary. This is a standard earnings release disclosure under Item 2.02 (Results of Operations and Financial Condition), furnished as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
HighPeak Energy issued a press release on August 10, 2026 announcing its second quarter 2026 financial and operating results, including net income of $82.3 million ($0.59 per diluted share), EBITDAX of $147.6 million, production volumes of 45.3 MBoe/d, and capital expenditures of $107.5 million.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
CervoMed issued a press release on August 10, 2026, announcing financial results for the quarter ended June 30, 2026, including cash position ($24.9 million), R&D expenses ($4.3 million), G&A expenses ($2.4 million), and net loss ($6.6 million). The filing explicitly states this is Item 2.02 disclosure with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial results and material corporate updates (equity financings of $20.5 million, clinical trial progress, regulatory designations).
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
HireQuest issued a press release on August 10, 2026, reporting financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $8.1 million (up 6.0% YoY), net income of $2.7 million or $0.19 per diluted share (up from $0.08 in Q2 2025), and adjusted EBITDA of $4.6 million. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Fluent, Inc. issued a press release on August 10, 2026 announcing second quarter 2026 financial results, including Q2 revenue of $48.4 million, net loss of $6.2 million, and key operational metrics for Commerce Media Solutions. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes consolidated financial statements and detailed segment performance, making it material to investors' assessment of the company's financial condition and operational performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
FutureFuel Corp. issued a press release on August 10, 2026, announcing financial and operating results for Q2 and six months ended June 30, 2026. The disclosure includes detailed quarterly financial metrics (total revenues of $78.7 million, GAAP net income of $11.4 million, Adjusted EBITDA of $11.8 million), segment performance, and forward-looking guidance. This is a standard earnings release filed under Item 2.02 and furnished as Exhibit 99.1, which is material to investors assessing the registrant's financial performance and trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
DiaMedica disclosed its condensed consolidated financial results for the quarter ended June 30, 2026, via a press release attached as Exhibit 99.1. The filing includes quarterly financial metrics (cash position of $43.5 million, net losses of $10.1 million and $20.2 million for Q2 and six months respectively), operating cash flows, and expense breakdowns by category (R&D, G&A). This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and runway.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-10
Item 7.01
The Board declared a special dividend of $0.31 per share payable from proceeds of the sale of the Company's footwear business, with a record date of June 25, 2026 and anticipated payment date of August 20, 2026. This is a material capital distribution to shareholders funded by a significant asset sale, and the disclosure explicitly announces the dividend declaration and payment terms.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
Trump Media & Technology Group issued a press release on August 10, 2026, announcing its financial and operating results for the quarter ended June 30, 2026, disclosing a $238.1 million net loss, $1.7 million in revenue (up 89% year-over-year), total assets of $2.0 billion, and financial assets of $1.9 billion. This is a standard quarterly earnings disclosure furnished as Exhibit 99.1 under Item 2.02, which is the designated Item for earnings releases.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-08-10
Item 7.01
The filing discloses completion of a reorganization in which First Trust Senior Floating Rate Income Fund II (FCT) was reorganized into First Trust Flexible Income ETF (FFLX), with FCT's assets transferred to and liabilities assumed by FFLX, and shareholders receiving FFLX shares equal to their FCT net asset value. This constitutes a material change of control and restructuring of the registrant's legal form and investment structure, approved by shareholders on June 25, 2026 and completed on August 10, 2026.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-08-10
Item 7.01
The disclosure centers on the Board's decision to retain Benjamin Kortlang as a director following the 2026 annual meeting vote, combined with governance enhancements including Joseph Malchow's appointment as Chair of the Nominating and Corporate Governance Committee. While this involves board composition and leadership transitions, it does not fit the specific categories of exec_appointment or exec_departure—Kortlang is retained (not appointed or departing), and Malchow's committee chair role is a governance restructuring rather than a C-suite appointment. The event is clearly governance-related and material to investors assessing board composition and responsiveness to shareholder feedback, making governance_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-10
Item 8.01
Phillips Edison entered into a sales agreement on August 10, 2026 to offer and sell up to $400 million of common stock through an at-the-market offering program with multiple agents, including forward sale agreements. This is a material dilutive equity issuance that would affect shareholder ownership and the total mix of information available to investors. The filing explicitly describes the continuous offering program, the use of forward sale agreements, and the intended use of proceeds for debt repayment and acquisitions.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-08-10
Item 8.01
The filing discloses Dynamic Aerospace Systems' Q2 2026 financial results, reporting a GAAP net loss of $2.18 million for the quarter ended June 30, 2026. The shareholder letter from CEO Kent B. Wilson provides detailed financial performance metrics, including adjusted operational loss calculations and non-GAAP reconciliations. This constitutes a quarterly earnings release, which is material to investors assessing the company's financial condition and operational performance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-10
Item 8.01
The filing discloses that CEA Industries received a Nasdaq compliance notice on May 7, 2026 for failure to hold an annual meeting within twelve months (Nasdaq Listing Rule 5620(a)), which is a continued listing requirement violation. Although the company subsequently regained compliance by holding its 2026 Special Meeting on July 22, 2026 and received confirmation on August 5, 2026, the core event is the delisting risk that materialized and was then remedied. This is material to investors as it directly affects the company's ability to maintain its Nasdaq listing.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-10
The filing discloses a comprehensive executive leadership transition effective August 6, 2026, with the departure of two senior officers (LOKE WENG CHAN and Dr. JIMMY LOKE) and the appointment of five new executives including a new President and CEO (CHAI KOK LEONG), CFO and Board Chairman (GILBERT LOKE), CMO (LOUIS TANG), Chief Strategy Officer (Dr. JIMMY LOKE in a new role), and CTO (ZHENG XIANG). While both departures and appointments occur, the filing's primary focus and structure emphasize the appointment of new leadership across all major executive functions, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-08-10
The filing discloses Item 4.01 Changes in Registrant's Certifying Accountant. On August 4, 2026, the Audit Committee dismissed Grant Thornton Audit and Accounting Limited (Dubai Branch) as the independent registered public accounting firm and appointed PricewaterhouseCoopers Limited Partnership Dubai Branch as the new auditor, effective for the fiscal year ending December 31, 2027. This is a clear auditor change event involving both dismissal of the prior auditor and appointment of a new one.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
NESR reported Q2 2026 financial results with record revenue of $520.8 million (up 59.1% YoY), net income of $44.0 million (up 189.6% YoY), and diluted EPS of $0.43 (up 168.8% YoY), along with Adjusted EBITDA of $106.2 million (up 50.5% YoY) and strong cash flow generation.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 95%
filed 2026-08-10
The 6-K discloses a securities class action complaint filed on July 23, 2026, in New York Supreme Court naming Basel Medical Group Ltd and more than 30 other publicly traded companies as defendants, with service on the Company's process agent on August 5, 2026. This is a material litigation disclosure that would affect a reasonable investor's assessment of the Company's legal and financial exposure, even though the Company states it is unable to predict the outcome at this early stage.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
The 8-K discloses Tonix Pharmaceuticals' second quarter 2026 financial results under Item 2.02 (Results of Operations and Financial Condition). The press release reports Q2 2026 net product revenue of $13.5 million (vs. $2.0 million in Q2 2025), with TONMYA net sales of $11.0 million representing 197% quarter-over-quarter growth. The filing includes detailed financial metrics, operational highlights, and cash position ($176.2 million as of June 30, 2026), which are material to investors assessing the company's commercial execution and financial trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
The 8-K discloses Sharplink's financial results for Q2 2026 (three and six months ended June 30, 2026) via Item 2.02 and an attached press release (Exhibit 99.1). The press release presents condensed consolidated balance sheets, statements of operations, revenue highlights ($11.5M in Q2 2026 vs. $0.7M in Q2 2025), net loss ($394.3M in Q2 2026 vs. $103.4M in Q2 2025), and operational metrics including ETH holdings and treasury strategy updates. This is a standard quarterly earnings disclosure material to investors assessing the registrant's financial condition and performance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-10
The filing discloses publication of peer-reviewed preclinical research demonstrating Telomir-Zn's mechanism of action and anti-tumor activity in TNBC and prostate cancer models. This is a material operational/scientific milestone for a clinical-stage biotech company, supporting advancement toward Phase 1/2 trials. While not a traditional earnings release or regulatory approval, the publication represents meaningful progress in the company's development pipeline and would affect a reasonable investor's assessment of the lead program's viability.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
The filing discloses Outdoor Holding Company's financial results for the fiscal first quarter ended June 30, 2026, via Item 2.02 and an attached press release (Exhibit 99.1). The press release reports revenue growth of 22.1% to $14.5 million, return to profitability with net income from continuing operations of $3.6 million (versus a prior-year loss of $5.9 million), and Adjusted EBITDA more than doubling to $7.9 million. These are material quarterly earnings results that would affect a reasonable investor's assessment of the company's financial performance and trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
The 8-K discloses quarterly financial results for Q1 fiscal 2027 (quarter ended June 30, 2026) via Item 2.02, with a press release attached as Exhibit 99.1. The filing reports revenue of $110.8 million (6.4% growth), services revenue of $94.3 million (9.1% growth), improved operating cash flow, and updated full-year fiscal 2027 guidance. This is a standard earnings release disclosure material to investors assessing the company's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
The 8-K discloses SHF Holdings' financial results for Q2 2026 via Item 2.02 (Results of Operations and Financial Condition). The press release (Exhibit 99.1) announces Q2 2026 revenue of approximately $1.9 million (up 4.8% YoY), loan program income up 50.7% YoY, deposit balance growth of 6.8% YoY, and a net loss of approximately $(1.5) million. This is a standard quarterly earnings release with detailed financial statements and operational highlights, material to investors assessing the company's financial performance and strategic progress.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
The 8-K discloses under Item 2.02 (Results of Operations and Financial Condition) a press release announcing AIM ImmunoTech's financial results for the quarter ended June 30, 2026. The press release reports Q2 2026 financial metrics including cash position ($9.9M vs $3.0M year-end 2025), R&D expenses ($589K vs $1.2M prior year), G&A expenses ($2.9M vs $1.5M prior year), and net loss of $(3.8M) or $(0.43) per share. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and operational progress.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-08-10
Item 1.01
This Item 1.01 discloses entry into a definitive merger agreement between Tri-County Financial Group, Inc. (TYFG) and HBT Financial, Inc., whereby TYFG will merge into HBT in a transaction valued at approximately $204.6 million. The agreement specifies consideration of 2.4589 HBT shares or $71.01 cash per TYFG share, with customary closing conditions including stockholder approval and regulatory approvals. This is a material acquisition/change of control transaction that would materially affect a reasonable investor's assessment of TYFG.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-10
The filing discloses an operational and strategic update on Bitmine's cryptocurrency treasury holdings and business activities, including ETH accumulation progress (5.81 million tokens, 4.8% of total ETH supply), staking operations (MAVAN platform generating projected $257-294 million annualized revenues), and a $4 billion share repurchase program with 19.1 million shares repurchased since July 2026. While the press release contains forward-looking statements and market commentary, the core disclosure centers on material operational developments in the company's digital asset treasury strategy and capital allocation decisions that would affect a reasonable investor's assessment of the registrant's business trajectory and financial position.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-10
The filing discloses an amendment to a material business combination agreement between HVII, Merger Sub, and ONE Nuclear Energy LLC. Item 1.01 explicitly states that on August 7, 2026, the parties entered into the "Third Omnibus Amendment" extending the outside date for consummating the Business Combination from August 15, 2026 to September 30, 2026, and increasing the maximum loan amount under the Promissory Note from $316,975 to $620,000. This is a material amendment to an ongoing M&A transaction that would significantly affect investor assessment of the deal's timing and financing.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-10
Item 5.02
The filing discloses both a departure (Martin Shen's resignation as CEO and Director on August 4, 2026) and an appointment (Jolie Kahn's appointment as CEO and Director effective the same date). While both events occurred, the principal disclosed action centers on the appointment of a new CEO with extensive qualifications in corporate finance, public company leadership, and securities law. The detailed biographical information and forward-looking tone emphasize the appointment as the material event driving the disclosure.
View raw filing on EDGAR →